Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous s stock reports and market updates.
Amedisys Inc. (NASDAQ: AMED) shares fell 3.33 percent to close at $15.66 a share Tuesday. The stock traded between $14.47 and $16.16 on volume of 475,085 shares traded. Analysts at Oppenheimer have recently downgraded the company’s rating to “perform” from “outperform”. Shares of Amedisys have gained approximately 7.0 percent year-to-date.
Find out more about Amedisys including full access to the free equity report at:
Accuray Incorporated (NASDAQ: ARAY) shares increased 0.62 percent to close at $9.78 a share Tuesday. The stock traded between $9.77 and $10.16 on volume of 1.24 million shares traded. Analysts at BTIG have recently initiated coverage on the company with a “buy” rating and a price target of $12.00. Shares of Accuray have gained approximately 12.0 percent year-to-date.
Find out more about Accuray including full access to the free equity report at:
NxStage Medical, Inc. (NASDAQ: NXTM) shares fell 5.80 percent to close at $13.81 a share Tuesday. The stock traded between $13.74 and $14.34 on volume of 1.97 million shares traded. Analysts at Wells Fargo have recently downgraded the company’s rating to “underperform” from “market perform”. Shares of NxStage Medical have gained approximately 38.0 percent year-to-date.
Find out more about NxStage Medical including full access to the free equity report at:
Varian Medical Systems, Inc. (NYSE: VAR) shares increased 0.44 percent to close at $84.68 a share Tuesday. The stock traded between $83.60 and $85.50 on volume of 647,044 shares traded. Analysts at BTIG have recently initiated coverage on the company with a “neutral” rating. Shares of Varian Medical Systems have gained approximately 9.0 percent year-to-date.
Find out more about Varian Medical Systems including full access to the free equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Research Driven Investing